Behringwerke Aktiengesellschaft

Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Roussel Uclaf

Dade Behring Marburg Gmbh

Laboratoires Hoechst

Hans H Sedlacek

Klaus Bosslet

Gerhard Dickneite

Gerhard Seemann

Bernhard Auerbach

Hans U Schorlemmer

Hans P Kraemer

Hans-Ulrich Schorlemmer

Lucien Nedelec

Wilfried Schwab

Bansi Lal

Robert R Bartlett

Jacques Guillaume

Ulrich Gebert

Cenek Kolar

Richard H Rupp

Jean-Claude Jacquesy

Peter Hermentin

Claude Monneret

Michel Koch

Axel Zeeck

Jorg Czech

Manfred Gerken

Jean-Pierre Gesson

Jean-Claude Florent

Roland Kurrle

Friedrich R Seiler

Francedillaois Tillequin

Peter Pfleiderer

Hans Zahner

Rolf Muller

Peter C Schmidt

Ralf Thiericke

Martine Mondon

Joachim Hilfenhaus

Dieter Hoffman

Ramchandra G Naik

Christian Marchandeau

J Org Czech

Ernst-Jurgen Kanzy

Gilbert Gaudel

Takako Katoh

Brigitte Renoux

Gerhard Luben

Harald Perschbacher

Klaus-Jurgen Steffens

Paul H List

The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or 'humanized' MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.

Chimeric antibody against tumor associated antigens and its use in diagnosing tumors

Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Monoclonal antibodies with specificity for membrane-associated antigens and methods of using them in detection of tumor-associated antigens arc described.

Monoclonal antibodies with specificity for membrane-associated antigens

The invention relates to a method of using a pair of leucine zipper peptides for in vitro diagnosis, in particular, for the immunochemical detection and determination of an analyte in a biological liquid. In one method, the first leucine zipper peptide is immobilized by attaching it to a solid support, the second leucine zipper peptide is coupled to a specific binding partner for the analyte, the two peptides are brought into contact, the sample of the biological liquid is brought into contact with the immobilized first peptide and the specific binding partner for the analyte, and the amount of analyte bound to the binding partner is determined. The leucine zipper peptides are preferably v-fos and c-jun.

Use of pairs of leucine zipper peptides in immunoassay methods

Glycosylated prodrugs, their method of preparation and their uses

Compounds of the formula I ##STR1## in which the substituents R.sub.1 -R.sub.5 and n and m are as defined are suitable for controlling tumors.

Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one

Use of derivatives of 9,10-dihydrophenanthrene for the preparation of an

Manumycin derivatives and the use thereof

Pharmaceuticals containing or composed of at least one compound of the formula I and/or one of its physiologically tolerated salts where appropriate, where the compounds of the formula I can, where appropriate, be in the form of pure stereoisomers or mixtures thereof; formula I is: ##STR1## in which R.sup.1 =organic radical or halogen,

Pharmaceuticals, phosphorus-containing 2-isoxazolines and isoxazoles

The use of the thiazole derivative tiprotimod for the preparation of a pharmaceutical for the therapy of virus infections is described.

Use of the thiazole derivative tiprotimod for the preparation of an

The use of 15-deoxyspergualine for the preparation of a pharmaceutical for the therapy of degenerative diseases is claimed.

Use of 15-deoxyspergualine as a pharmaceutical

A pharmaceutical formulation for the parenteral, in particular intravenous, administration of sparingly soluble substances is obtained when the very finely ground substance, with a maximum particle diameter of 3 .mu.m, is dispersed in an oil phase which contains emulsifier, and this mixture is emulsified with water for injection, is rendered isotonic and is homogenized using a high-pressure homogenizer, so that the resultant product is a solid/liquid/liquid disperse system.

Pharmaceutical formulation and process for its preparation

A fission product of an immunoglobulin having an immunologically functioning Fc-portion is bound to a carrier by adhesion or a chemical reaction. It can be used in an immunological analytic process for the determination of Fc-reactants in aqueous solutions.

Carrier-bound immunoglobulin fission product and its use in immunologic

Growing community of inventors

Marburg, Germany

Hans H Sedlacek